Share：
Share this content in WeChat
X
[Chinese][PDF]84578
• Clinical Article •
The diagnostic value of mp-MRI for detecting transition zone prostate cancer based on PI-RADS V2
PENG Feng-he  SHEN Xiu-zhi  CAI Jian-xin  LI Yan-cui  KONG Guang-qi  PENG Ru-chen 

DOI:10.12015/issn.1674-8034.2018.12.008.


[Abstract] Objective: To investigate the diagnostic value of multiparametric MRI (mp-MRI) for detecting clinically significant transition zone prostate cancer (TZ-PCa) based on prostate imaging-reporting and data system version 2 (PI-RADS V2).Materials and Methods: Totally 105 patients undergoing prostate mp-MRI consisting of T2WI, diffusion weighted imaging (DWI) and dynamic contrast-enhanced MRI (DCE-MRI) were included and analyzed retrospectively. Among them 41 were confirmed TZ-PCa, 64 benign prostatic hyperplasia (BPH) by pathology within ≤1 week from MRI. T2WI, DWI, DCE-MRI and mp-MRI (T2WI+DWI) were scored based on PI-RADS V2 by two diagnostic physicians, as well as calculating their sensitivity and specificity taking pathological results as gold standard. Receiver operating characteristic (ROC) curve was drawn and the area under curve (AUC) was performed to analyze the diagnostic efficiency of TZ-PCa with different protocols.Results: Inter-observer agreement of PI-RADS V2 score was good (Kappa value=0.83). The AUC of T2WI, DWI, DCE-MRI and mp-MRI for the diagnosis of TZ-PCa with PI-RADS V2 were 0.914, 0.887, 0.773, 0.927, respectively. The AUC was not statistically significant difference between T2WI and mp-MRI (P=0.107), and statistically significant difference of AUC was found between the rest of each other scan protocols. The sensitivity and specificity were 85.4%, 84.4% for T2WI alone, 78.0%, 81.3% for DWI alone, 78.0%, 76.6% for DCE-MRI alone and 92.7%, 83.9% for mp-MRI.Conclusions: Multiparametic MRI based on PI-RADS V2 has important guiding significance in diagnosis of clinically significant transition zone prostate cancer.
[Keywords] Prostatic neoplasms；Transition zone；Magnetic resonance imaging；Prostate imaging-reporting and data system

PENG Feng-he Department of Radiology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China

SHEN Xiu-zhi Department of Radiology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China

CAI Jian-xin Department of Radiology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China

LI Yan-cui Department of Radiology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China

KONG Guang-qi Department of Urology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China

PENG Ru-chen* Department of Radiology, Beijing Luhe Hospital, Capital Medical University, Beijing 101149, China

*Correspondence to: Peng RC, E-mail: 13501271260@163.com

Conflicts of interest   None.

Received  2018-03-08
DOI: 10.12015/issn.1674-8034.2018.12.008
DOI:10.12015/issn.1674-8034.2018.12.008.

[1]
Reda I, Shalaby A, Elmogy M, et al. A comprehensive non-invasive framework for diagnosing prostate cancer. Comput Biol Med, 2017, 81(1): 148-158.
[2]
Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS prostate imaging-reporting and data system: 2015, Version 2. Eur Urol, 2016, 69(1): 16-40.
[3]
Turkbey B, Brown AM, Sankineni S, et al. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer. CA Cancer J Clin, 2016, 66(4): 326-336.
[4]
Barrett T, Turkbey B, Choyke PL. PI-RADS version 2: what you need to know. Clin Radiol, 2015, 70(11): 1165-1176.
[5]
Park SY, Jung DC, Oh YT, et al. Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers. Radiology, 2016, 280(1): 108-116.
[6]
牛翔科，刘伟，肖建明，等. PI-RADS v2在前列腺癌中的诊断价值分析．四川大学学报（医学版）, 2016, 47(5): 796-799.
[7]
王希明，包婕，朱默，等．第一版和第二版前列腺影像报告和数据系统评分对移行带前列腺癌的诊断价值．中华放射学杂志, 2017, 51(6): 427-431.
[8]
李拔森，王良．第二版前列腺影像报告和数据系统（PI-RADS）解读．中华放射学杂志, 2015, 49(10): 798-800.
[9]
李君，金彪，张海兵，等．磁共振DWI及动态增强对前列腺癌的诊断．现代泌尿外科杂志, 2012, 17(5): 473-476.
[10]
Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia, 2009, 11(2): 102-125.
[11]
孙丽娜，李前程，程凯亮，等．磁共振扩散加权成像鉴别诊断前列腺癌与良性前列腺增生的Meta分析．中国医学影像学杂志, 2013, 21(6): 464-467.
[12]
Oto A, Kayhan A, Jiang Y, et al. Prostate cancer: differentiation of central gland cancer from benign prostatic hyperplasia by using diffusion-weighted and dynamic contrast-enhanced MR imaging. Radiology, 2010, 257(3): 715-723.
[13]
可赞，邓明，王良．基于PI-RADS多参数MRI诊断移行带前列腺癌的研究进展．放射学实践, 2015, 30(8): 880-884.
[14]
姬广海，郑义,孛茹婷，等.多参数MRI对中央腺体前列腺癌的诊断价值．中国医学影像学杂志, 2016, 24(8): 591-595.
[15]
赵丽霞，吴蓉．前列腺癌影像诊断现状及新进展．中华临床医师杂志（电子版）, 2013, 7(21): 9659-9661.
[16]
Iwazawa J, Mitani T, Sassa S, et al. Prostate cancer detection with MRI: is dynamic contrast-enhanced imaging necessary in addition to diffusion-weighted imaging. Diagn Interv Radiol, 2011, 17(3): 243-248.
[17]
马露，叶慧义，王海屹．动态增强MRI定量分析在前列腺癌诊断中的应用．微创泌尿外科杂志, 2017, 6(2): 119-123.
[18]
王蕊，高歌，王慧慧，等．评价第二版前列腺影像报告和数据系统对前列腺临床显著癌的检出效能．中国医学影像技术, 2016, 32(12): 1799-1802.
[19]
李拔森，王良，邓明，等．多参数MRI前列腺影像报告和数据系统评分与经直肠超声引导下穿刺病理的相关性分析．磁共振成像, 2016, 7(5): 321-326.
[20]
Tan N, Lin WC, Khoshnoodi P, et al. In-bore 3-T MR-guided transrectal targeted prostate biopsy: prostate imaging reporting and data system version 2-based diagnostic performance for detection of prostate cancer. Radiology, 2017, 283(1): 130-139.
[21]
雷李智，许乙凯，侯美蓉，等．联合第2版前列腺影像报告与数据系统评分与前列腺特异性抗原的Logistic回归预测模型诊断移行区前列腺癌．中国医学影像技术, 2017, 33(7): 1047-1051.

PREV Imaging features of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in adults
NEXT Automatic segmentation and classification evaluation based on semi-quantitative score of magnetic resonance imaging of knee articular cartilage
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn